PRKAB1 and diabetes mellitus: However, because the pharmaceutical industry continues to search for novel specific AMPK agonists combating diseases like diabetes and cancer, the availability of such substances is likely going to increase, and the (mis)use of such in the hope for ergogenic purposes will likely follow.